Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 5/20 | 0.39 |
| ▸ | DHODH | Q02127 | 5/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 3/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.36 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3157325 | 0.85 | RORC (0.41) | CA2CA9RORCDHODHMAPK1 | |
| SCHEMBL4804222 | 0.83 | OPRM1 (0.43) | RORCDHODHTMIGD3ADORA1GAA | |
| SCHEMBL4798494 | 0.83 | RORC (0.40) | CA2CA9RORCDHODHMAPK1 | |
| SCHEMBL3171622 | 0.81 | HTR2B (0.42) | CA2CA9MAPK1LMNAHTR2B | |
| SCHEMBL4798462 | 0.79 | SLC27A1 (0.47) | LMNATMIGD3ADORA1 | |
| SCHEMBL4805581 | 0.75 | RORC (0.45) | RORCDHODHLMNAADORA1 | |
| SCHEMBL3169724 | 0.75 | TMIGD3 (0.49) | MAPK1LMNATMIGD3ADORA1GAA | |
| SCHEMBL4802777 | 0.74 | F2 (0.43) | RORCDHODHGAA | |
| SCHEMBL4804431 | 0.73 | NPC1 (0.46) | LMNAGAA | |
| SCHEMBL4802788 | 0.73 | TMIGD3 (0.40) | MAPK1LMNATMIGD3ADORA1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7348347-B2 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds | GRUENENTHAL GMBH (DE) | 2008-03-25 | — | — | US | claimed |
| US-20070027315-A1 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds | GRUENENTHAL GMBH (DE) | 2007-02-01 | — | — | US | claimed |
| US-7348347-B2 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds | GRUENENTHAL GMBH (DE) | 2008-03-25 | — | — | US | disclosed |
| US-20070027315-A1 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds | GRUENENTHAL GMBH (DE) | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027315-A1 | Substituted 4,5,6,7-tetrahydrobenzthiazol-2-ylamine compounds | TPH2, HTR6, TPH1 | CA2 2187/4885CA9 4657/4885RORC 746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.